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Detection of breast cancer micrometastases based on specific
genetic markers may provide useful information to guide early
therapeutic decisions. Immunohistochemical (IHC) and reverse
transcription polymerase chain reaction (RT-PCR) methods
offer the potential of improved sensitivity for detection of
micrometastatic carcinoma cells that are missed by conventional
histopathological examination (Raj et al, 1998; Pelkey et al, 1996;
Lockett et al, 1998). Various biological markers have been
proposed for the detection of breast cancer cells using these tech-
niques, including keratin 19, muc1, EMA, CEA, HCG (Hoon et al,
1996; Tsuchiya et al, 1996; Mori et al, 1996; Schoenfeld et al,
1997). However, the frequency of expression of these markers is
often related to tumour differentiation and is not always confined
to breast tissue (Zippelius et al, 1997). Another promising breast
specific marker is prolactin inducible protein (PIP) which is also
known as gross cystic disease fluid protein-15 (GCDFP-15)
(Haagensen et al, 1990; Wick et al, 1989; Murphy et al, 1987).
IHC studies have previously shown that PIP is frequently
expressed in human breast carcinomas and is comparatively
specific for breast cancer (Wick et al, 1998; Wick et al, 1989;
Mazoujian et al, 1983). While PIP expression is found to occur in
tumours arising from skin and salivary gland, distinction from
breast cancer is rarely a clinical issue and PIP protein has already
found practical application as a marker for the recognition of
breast origin of metastatic tumours (de Almeida & Pestana 1992;
Fiel et al, 1996; Ormsby et al, 1995; Monteagudo et al, 1991).
However, PIP is a secreted protein that is readily detectable in
benign breast cyst fluid and plasma, which may impact on the
significance of IHC detection of the protein (Haagensen et al,
1990). We have recently used PIP alongside other markers to
explore its value in detection of breast micrometastases (Lockett et
al, 1998a; Lockett et al, 1998b), however, the incidence and
pattern of PIP expression at the level of RT-PCR is not known. Our
purpose in this study was to evaluate the potential of PIP mRNA as
a marker for the detection of breast cancer cells by assessing the
frequency of PIP mRNA expression in human breast cell lines and
in breast tumors in relation to tissue composition and pathology.
MATERIALS AND METHODS
Human cell lines
The human breast cancer cell lines (T47D, ZR 75, MDA-MB-231,
BT 474 and MCF-7) and the normal human breast cell line,
HBL-100, were obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). All cell lines were
cultured as described previously in Dulbecco’s modified Eagle’s
medium (DMEM) containing 10% fetal bovine serum (FBS), 1% 1
mg ml–1 insulin, 1% 35% (w/v) glucose, 1% penicillin–strepto-
mycin and 1% L-glutamine. Cells were harvested with 5% trypsin
(v/v) from culture flasks.
Human tissue samples
A cohort of 97 primary breast tumour samples was obtained from
the Manitoba Breast Tumor Bank located in the Department of
Pathology, Faculty of Medicine, University of Manitoba. The
cohort was selected initially on the basis of oestrogen receptor
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(ER) status so as to ensure a wide range of ER levels to determine
any correlation between ER status and PIP expression. The tumour
bank collected all breast tumour specimens on ice which were then
bisected to provide mirror image tissues for formalin-fixed,
paraffin-embedded blocks and matching frozen tissue blocks
stored at –70°C (Hiller et al, 1996). The pathological and histolog-
ical parameters (including tumour type, grade, invasive and
normal cell content) were then assessed uniformly by one patholo-
gist in sections from the paraffin block and entered into a database
enabling selection by specific criteria (Watson, 1996). Tumour
grading was performed using the Nottingham system (Elston &
Ellis, 1991) and steroid receptor levels were measured by ligand
binding assay performed on an adjacent piece of tumour tissue. ER
and progesterone receptor (PR) values above 3 fmol mg–1 and 15
fmol mg–1 total protein respectively were deemed positive. A
second cohort of five primary tumours was also selected from the
tumour bank on the basis of association with matching frozen
tissue in the bank from a synchronous nodal metastasis.
A third cohort of axillary lymph node samples from 32 patients
with metastatic breast tumours undergoing breast cancer surgery
was obtained from the Department of Surgery at the Medical
University of South Carolina. These samples were collected
prospectively from patients with primary tumours associated with
a range of clinical stages (12 stage I, 12 stage II, eight stage III)
and included 16 samples from patients who were histologically
node-positive and 16 from patients who were node-negative.
Immediately after resection, the axillary lymph node specimens
were identified and separated from the specimen by a pathologist.
All lymph nodes > 1 cm were bisected, with half of the node sent
for routine histological evaluation and the other half for RT-PCR
screening. The RT-PCR screened lymph nodes were snap frozen at
–70°C until being processed to extract total RNA.
Normal tissue samples from several potential sites of breast
tumour metastasis were also obtained from the Manitoba Breast
Tumor Bank. Normal human peripheral blood lymphocytes (PBL)
were isolated from 5 ml blood samples drawn from each of 11
healthy volunteers (females and males, 22–29 years old). The red
blood cells in each 5 ml samples were lysed by adding 25 ml of
lysing reagent (140 mM NH4Cl2 and 17 mM Tris, pH 7.6) and
leaving the mixture to incubate for 10 min at 37°C. This was
followed by centrifugation at 2000 rpm for 10 min to pellet white
blood cells, removal of the supernatant and re-suspension of PBLs
in PBS.
Sensitivity assay
To determine the sensitivity of the RT-PCR assay, T47D human
breast cancer cells (PIP+) were diluted into a background of MDA-
MB-231 cells (PIP–) so as to obtain a range of concentrations of
PIP+ cells from 1 to 1000 cells in 106 PIP– cells prior to RNA
extraction and RT-PCR assay. Cell numbers were determined by
directly counting aliquots of cells in suspension under a micro-
scope using a haemocytometer.
RNA extraction and RT-PCR
Total RNA from all tumour, tissue and cell pellet samples was
isolated using similar commercial extraction reagents, either Tri-
reagent or Tri-zol reagents and protocols according to the manu-
facturer’s instructions (Molecular Research Center Inc, Cincinnati,
OH, USA and BRL). RNA samples were quantified by performing
spectrophotometry. Samples were presumed to be free of DNA
and proteins if the OD 260/280 ratio was 1.6–1.8. All RNA
samples were stored at –70°C until further use.
Reverse transcription of mRNA to cDNA was performed as
previously described (Hiller et al, 1996) with the following modi-
fications. All PCR primers were designed to cross intron–exon
boundaries. The PIP primers were sense (5¢-GCTCAGGACAA-
CACTCGGAA-3¢) and antisense (5¢-ATAACATCAACGACG-
GCTGC-3¢) corresponding to positions 107 and 356 of the cDNA
sequence (Murphy et al, 1987), and GAPDH primers were sense
(5¢-ACCCACTCCTCCACCTTTG-3¢) and antisense (5¢-CTCT-
TGGCTCTTGCTGGG-3¢) (Ercolani et al, 1988). Preliminary
experiments were performed with cell line and tumour RNA
samples to establish the appropriate RNA input and PCR cycle
number conditions to achieve amplification with both PIP and
gluceraldehyde 3-phosphate dehydrogenase (GAPDH) primers in
the linear range in a typical sample. Amplification of GAPDH or
actin was then performed in duplicate samples, for every experi-
mental sample, to provide an internal indicator as to the quality of
the cDNA of each sample. The PCR consists of an initial 5-min
preheating step at 94°C, followed by repeated cycles of a 1-min
denaturing step at 94°C, a 1-min primer annealing step at 54°C,
and a 90 s elongation step at 72°C. Cycle numbers to achieve
amplification in the linear range were 40 for PIP and 35 for
GAPDH and actin. Once thermal cycling was completed, samples
underwent one final elongation step at 72°C for 7 min. Tumours
were processed in batches of 12 samples, from frozen sectioning to
RNA extraction, RT in triplicate and PCR. For each batch controls
included RT- and RNA-controls, and both PIP+ (T47D) and PIP –
(MDA-MB-231) RNA controls. All primary tumour PCR signals
were assessed in gels and autoradiographs by video image capture
and computer analysis using MCID-M4 Imaging Research Inc,
version 2.0 image analysis program. PIP expression was standard-
ized to GAPDH expression assessed in separate PCR reactions
from the same RT reaction and run in parallel on the same gel and
then expressed relative to the levels in the T47D cell line standard.
To correct for any differences in processing between gels PIP
levels were further standardized to a set of PCR product standards
incorporated into each gel.
Southern and dot blot analysis
For Southern blot analysis following PCR amplification, PCR
products were loaded into a 1% agarose gel. After electrophoresis
the gel was exposed to ethidium bromide, illuminated with ultra-
violet light and photographed. For hybridization, gels were de-
natured in 0.5 M sodium hydroxide (NaOH), 1 M sodium chloride
(NaCl) for 30 min at room temperature and neutralized for 30 min
in 1.5 M Tris–HCl pH 7.4, 3 M NaCl. PCR product cDNA was then
transferred to Zeta-Probe membrane according to the Zeta-Probe
protocol (Bio-Rad Laboratories, Hercules, CA, USA) and
membranes were then dried in an 80°C oven for 30 min. For
probing membranes were prehybridized with 10 ml of hybridiza-
tion solution (50 ml of formamide, 12 ml of 1 M Na2HPO4, 5 ml of
5 M NaCl, 7 g of sodium dodecyl sulphate (SDS), and 200 µl of
0.5 M EDTA in 100 ml with ddH2O) at 42°C for 2 h with agitation.
Hybridization was then conducted at 42°C for 24 h with a hPIP
cDNA probe (Murphy et al, 1987) 32P labelled by the random
priming method and purified with a NICK chromatography
column (Pharmacia Biotech, Inc.). Hybridization membranes were
washed at room temperature for 1 h in a solution of 2 ´ SSC1004 JW Clark et al
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(standard saline citrate) and 0.1% SDS, then 1 h in 0.5 ´ SSC and
0.1% SDS, and 1 h in a 65°C waterbath in 0.1 ´ SSC and 0.1%
SDS. Bands were then visualized after autoradiography for 2–6 h.
For dot blot analysis, 1 µl of each PCR reaction sample was
deposited on a strip of Sure Blot Hybridization Membrane (Oncor,
Gaithersburg, MD, USA) and left to dry for 5 min. The membrane
was incubated for 5 min in a solution of 0.2 M NaOH at room
temperature after which the strip was incubated for another 30 min
at 56°C in Blocking Buffer (0.2% I-Block; Tropix, Bedford, MA,
USA), 1 ´ PBS, 0.5% SDS). The same PIP cDNA probe (Murphy
et al, 1987) was labelled using alkaline phosphatase as previously
described (Vary et al, 1996) and then added to the same tube at a
1:3000 dilution of stock (50 ng ml–1) and hybridized for 15 min.
The membrane was then washed 3 times for 10 min in Wash
Buffer (10 ´ PBS, 0.5% SDS) and twice in AMPPD Buffer (1 mM
magnesium chloride hexahydrate, 0.1 M diethanolamine, pH 10).
Finally, the membrane was incubated 30 min in the dark with 1%
CSPD (Tropix, Bedford, MA, USA) in AMPPD buffer. Dots were
visualized by exposure to 43 autoradiography film for 10 min.
Immunohistochemistry and in situ hybridization
Immunohistochemical detection of PIP expression was performed
using a commercially available monoclonal antibody (Signet
Laboratories Inc, Dedham, MA, USA) and protocol as recom-
mended. PIP was assessed in paraffin sections from a subset of 19
primary tumours, selected to correspond to a wide range of PIP
mRNA levels as determined by the RT-PCR assay based on frozen
tissue sections from the same cases. PIP protein was scored by
estimating the average signal intensity (on a scale of 0–3) and the
proportion of cells showing a positive signal and scored as 0
(none), 0.1 (less than one-tenth), 0.5 (less than one-half), or 1.0
(greater than one-half). The intensity and proportion scores were
then multiplied to give an overall score. In situ hybridization was
performed as previously described (Leygue et al, 1996) on 5-mm
paraffin sections from normal and tumour tissue with both sense
and antisense PIP riboprobes synthesized using UTP (35S) to label
the probes using RiboprobeR Systems (Promega, Madison, WI,
USA) according to the manufacturer’s instructions.
RESULTS
Analysis of sensitivity and PIP expression in cell lines
Multiple experiments were performed to determine the threshold
for detection of PIP+ cells in a background of PIP– cells, using the
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Figure 1 PIP mRNA expression in breast tumours. The upper panels show
a representative set of 12 primary tumours (A) and a set of five cases
(B, TN 1–5) comprising primary breast tumours (1) and their corresponding
nodal metastases (2) analysed for PIP mRNA levels by RT-PCR – Southern
blot. Corresponding GAPDH levels, determined as described in Materials
and Methods relative to T47D cells and a reference tumour (positive
controls) and MDA-MB-231 cells (negative control) are also shown. T47D
RNA subjected to reverse transcription reaction without RT-enzyme and
subsequent PCR is also shown (RT-control). In the lower panel the chart
shows a graphical representation of the level of PIP mRNA expression in
tumours relative to ER status (C). Tumour case numbers 1–30 are ER–
(< 3 fmol mg–1 protein), 31–49 are ER low positive (3–20 fmol mg–1 protein)
and 50–97 are ER high positive (> 20 fmol mg–1 protein)
Table 1 Relationship between mean PIP mRNA levels in primary breast
tumours and prognostic parameters
n Mean (s.d.) P-value
ER –ve 30 0.69 (1.4) 0.0004
+ve 67 2.12 (3)
PR –ve 52 1.04 (1.8) 0.0167
+ve 45 2.42 (3.3)
Grade low 16 2.59 (3.5)
mod 41 1.83 (2.9) 0.0195
high 40 1.16 (1.9)
Nodal status +ve 37 2.09 (3.3) NS
–ve 42 1.18 (1.8)
unknown 18
Size <2 cm 14 2.39 (4.5)
2–5 cm 45 1.36 (2.1) NS
> 5 cm 16 1.33 (1.9)
Unknown 22
PIP mRNA score (mean and s.d.) shown was derived as described in
Materials and Methods. P-values correspond to Spearman correlation test
Table 2 PIP RT-PCR screening of axillary lymph nodes compared to routine
histopathology
Pathology
+ve –ve Total
RT-PCR +ve 11 (69%) 6 (37%) 17 (53%)
–ve 5 (31%) 10 (63%) 15 (47%)
Total 16 (50%) 16 (50%) 32 (100%)PIP expression in breast cancer 1005
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RT-PCR/Southern blot assay. In different experiments the detec-
tion limit varied between 10 and 50 PIP+ cells in a background of
1 ´ 106 PIP– cells in different experiments (data not shown).
Of the six human breast cell lines (T47D, ZR 75, BT 474, MCF-
7, MDA-MB-231 and HBL-100) that were analysed, four showed
positive expression of PIP mRNA (data not shown). The rank
order of expression amongst the PIP+ cell lines was: T47D > ZR
75 > HBL-100 > BT 474.
Analysis of PIP mRNA expression in human breast
tumours
PIP mRNA expression in 97 primary tumours was assessed by
three independent RT and PCR reactions and expressed as a PIP
mRNA score. This was calculated from the mean intensity of PIP
mRNA signals for each tumour, standardized to the GAPDH
signal from three separate PCR reactions performed on the same
RT reactions and then standardized to the reference PIP signal as
determined in the T47D cell line (Figure 1). PIP was negative or
very low (< 5% of the T47D level) in eight tumours (8% cases).
Amongst the PIP+ tumours, 37 (38% cases) expressed PIP at levels
between 5% and 50% of that of the T47D cell, 30 (31% of cases)
expressed PIP at levels that were similar, between 50% and 200%,
and 22 (23% of cases) expressed PIP at higher levels. Further
analysis of PIP expression levels in relation to clinical-patho-
logical factors found a significant correlation between higher
levels of PIP expression in the primary tumours and higher ER
(P = 0.0004, r = 0.32) and PR levels (P = 0.0167, r = 0.24) and
lower Nottingham tumour grade score (P = 0.0195, r = 0.24,
Spearman correlation test). Similar analysis of these same parame-
ters as discontinuous variables was performed and confirmed these
associations. Mean (s.d.) PIP mRNA levels were higher in
ER+ (n = 67, 2.12(3.01)) versus ER– (n = 30, 0.69(1.39)) tumours
(P = 0.0004 Mann–Whitney test), PR+ (n = 45, 2.42(3.33)) versus
PR– (n = 52, 1.04(1.78) tumours (P = 0.001). PIP mRNA levels also
increased from well differentiated to poorly differentiated tumours
when assessed as three grade categories, although these differ-
ences fell short of achieving statistical significance (low-grade,
n = 16, 2.59(3.49), moderate-grade, n = 41, 1.83(2.92), high-grade,
n = 40, 1.15(1.95), P = 0.099 ANOVA test). No relationship was seen
between PIP mRNA expression and tumour size or nodal status
(Table 1).
In five additional cases with matching primary and nodal metas-
tasis tissue, analysis confirmed that PIP expression is conserved at
similar levels between primary and metastatic cells (Figure 1B).
Furthermore, RT-PCR analysis of lymph nodes from three patients
undergoing elective carotid endarterectomy without any current or
prior history of cancer was negative. Detection of PIP mRNA
expression was also performed on axillary lymph nodes from 32
different patients using the same RT-PCR assay but with minor
modifications to the method of detection. This assay used the same
PCR assay and primers and PIP cDNA probe, but detection was
performed by use of a non-radioactive alkaline phosphatase
labelling method for the probe applied to a dot blot for detection of
the PCR product. Overall PIP mRNA was detected in 17/32 lymph
nodes (53%) and increasing PIP positivity reflected the tumour
stage with 2/12 (17%) stage I cases positive compared to 9/12
(75%) stage II and 6/8 (75%) of stage III cases positive by RT-
PCR assay. Amongst the subset of cases that were positive by
histology, 11/16 (69%) were also positive by PIP RT-PCR and
5/16 (31%) were negative for PIPmRNA. Amongst the lymph
nodes that were negative by histology, 6/16 (37%) were PIP RT-
PCR positive (Table 2).
Immunohistochemistry and in situ hybridization
PIP mRNA levels determined by RT-PCR assay was compared to
protein levels assayed in a subset of 19 cases by immunohisto-
Table 3 Correlation between PIP protein and mRNA expression in a subset
of 19 tumours
Case no. Int % PIP IHC PIP RT-PCR
11913 [0 ´ 0] 0 0.023
11365 [1 ´ 0.1] 0.1 0.030
11657 [1 ´ 0.1] 0.1 0.048
10927 [1 ´ 0.5] 0.5 0.073
10970 [0 ´ 0] 0 0.170
11097 [2 ´ 0.5] 1 0.205
11836 [1 ´ 0.1] 0.1 0.350
11909 [2 ´ 1] 2 0.415
11526 [1 ´ 1] 1 0.469
10975 [2 ´ 1] 2 0.748
11341 [2 ´ 1] 2 0.964
11729 [1 ´ 0.1] 0.1 1.180
11339 [0 ´ 0] 0 1.840
11603 [3 ´ 0.1] 0.3 2.020
11288 [1 ´ 0.5] 0.5 2.470
11010 [2 ´ 1] 2 2.718
11903 [2 ´ 0.5] 1 4.320
11734 [1 ´ 1] 1 4.610
11152 [2 ´ 1] 2 6.190
Int = intensity, % = percentage of positive staining cells, PIP IHC = PIP
protein score derived as described in Materials and Methods from the
product of intensity and proportion of positive cells by immunohistochemistry
assay, PIP RT-PCR = PIP mRNA score as described in Materials and
Methods.
Figure 2 PIP mRNA expression in normal tissues. The upper panel shows
PIP levels in a set of normal tissues that are sites of breast cancer
metastasis (A) and the lower panel shows normal peripheral blood
lymphocytes isolated from venepuncture samples from five individuals (B).
Lanes are as follows: lane 4 normal male; lane 5 normal female, lanes 6 & 7,
8 & 9 and 10 & 11 are from three normal females on two separate occasions
each, lane 12, RNA minus PCR control
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chemistry (Table 3). PIP mRNA level correlated well with protein
level (r = 0.493, P = 0.0319, Spearman test) and using cut-off
points of < 5% PIPmRNA score and < 0.1 for PIP IHC score there
was also 89% concordance. Additional study by in situ hybridiza-
tion was performed on one tumour and one normal breast tissue
which confirmed previous observations that PIP mRNA expres-
sion was confined to epithelial cells but showed that PIP mRNA is
also expressed by both normal and neoplastic epithelial cells (data
not shown).
Analysis of PIP expression in normal human tissues
PIP mRNA was expressed at comparable levels to the T47D breast
tumour cell in several normal tissues examined including skin
salivary gland and ovary (Figure 2A). Very low levels of PIP
expression were observed in lung, whereas brain and liver were
negative. Immunohistochemistry analysis of skin demonstrated
that PIP protein expression was confined to sweat gland-like
structures in the dermis. Also mRNA analysis of PBLs from 11
normal people that were analysed, all were PIP– on at least one
occasion (Figure 2B). Repeat samples from three individuals
showed positive signals on other occasions that could not be
explained as systematic contamination at the RT-PCR step.
DISCUSSION
We have shown that PIP mRNA is frequently expressed by
primary breast tumours, although higher levels of expression occur
in well-differentiated and ER/PR+ tumours. Nevertheless, PIP
mRNA expression is also often conserved within the corre-
sponding lymph node metastases. Given confirmation of the rela-
tive specificity for breast tissue that has also previously been
established at the protein level by immunohistochemical studies
(Wick et al, 1989), it is clear that PIP mRNA expression is a poten-
tial marker for breast micrometastasis. The presence of occasional
positive signals in morphologically normal breast epithelium and
in peripheral blood samples from normal individuals also indicates
that, in common with most other markers, there is a need for
caution in the application of PIP as a single marker for metastatic
disease.
Many recent studies have concentrated on either IHC or
RT-PCR assays to detect specific markers that may indicate the
presence of micrometastatic disease. It is clear, however, that
several pitfalls need to be considered in the practical application of
individual markers (Dingemans et al, 1997). For example, while
IHC assay allows morphological confirmation of the origin of
positive signals it may detect some secreted proteins beyond the
context of the known cell of origin. In contrast, RT-PCR may be
more sensitive but does not allow direct confirmation of a positive
signal in the context of the appropriate cell morphology. RT-PCR
assay can also face problems that could arise from the presence of
pseudogene DNA sequences and low levels of background gene
expression in target tissues (Bostick et al, 1998; Lopez-Guerrero et
al, 1997; Zippelius et al 1997). Improvement in specificity, rather
than sensitivity, is needed. Amongst the several markers that have
been used for the detection of breast micrometastases, keratin 19
and muc1 have been the most widely used (Noguchi et al, 1996;
McGuckin et al, 1996). Improvements in specificity might best be
achieved through a combination of these with other markers (Min
et al, 1998) and a composite of technical approaches to their
detection, refined still further by an appreciation of the limitations
of individual markers (Zippelius et al 1997).
This study is aimed at establishing the potential of PIP as a
supplementary breast tumour cell marker. The GCDFP-15/PIP
gene encodes a protein that is found in high concentrations in gross
cystic disease of breast and in fluids of normal apocrine glands
such as sweat, tears and seminal fluid (Haagensen et al, 1990).
Given the low incidence and clinical distinctiveness of tumours
arising from other source tissues, PIP/GCDFP-15 protein has
already been considered as a breast cell specific marker, comple-
mentary to keratin (de Almeida & Pestana 1992). This potential is
based on the fact that PIP expression can be detected by IHC in up
to 76% of breast carcinomas (Wick et al, 1989) and there is a high
degree of concordance between PIP expression in 1° primary
carcinomas and nodal metastases (Mazoujian et al, 1989).
Expression of this marker has been associated with apocrine
differentiation, but there is not a direct concordance with Muc1
(Soomro & Shousha, 1992). While IHC, in situ hybridization and
Northern analysis have all found expression at a similar frequency
(Murphy et al, 1987; Pagani et al, 1994), the prevalence and
specificity of PIP mRNA for breast cancer at the sensitivity level
of RT-PCR has not been established. Using RT-PCR we have
found expression of PIP mRNA is readily detectable in most
human breast cell lines and breast tumours. This is more frequent
than previous IHC studies, which have reported the proportion of
PIP positivity between 55% and 72% (Wick et al, 1989; Mazoujian
et al, 1983). Not only is RT-PCR recognized as a highly sensitive
technique but it is clear that, in this study, the very high frequency
of PIP mRNA expression could in some cases be partly attribut-
able to weak signals that originated only within residual normal
breast elements. Consistent with this conclusion is the fact that a
minor component of histologically detectable normal epithelium
was found to be present within some (15%) of the 97 cases studied,
which also mostly showed low levels of PIP expression. We
estimate therefore that the true frequency of PIP mRNA positive
primary tumours is approximately 85% of cases. This is consistent
with our data where PIP mRNA expression was detected in
approximately 70% nodal metastases (Table 2) and that of others
(Mazoujian et al, 1989) and the fact that PIP expression is often
conserved between primary and nodal metastases (Figure 1B), as
also documented by others (Mazoujian et al, 1989; Wick et al,
1998). The presence of PIP mRNA in lymph nodes that are
histologically negative (on the basis of assessment of a single
haematoxylin and eosin (H&E)-stained diagnostic section) may
suggest the presence of occult metastases (Ferrari et al, 1997).
Previous studies have found micrometastases up to 25% lymph
nodes from breast cancer patients when this is pursued intensively
by histology and immunohistochemistry applied to serial sections,
(McGuckin et al, 1996) and in 15–25% of cases when RT-PCR
analysis is applied using other tumour markers such as muc1
(Noguchi et al, 1994) or b-human chorionic gonadotrophin (Hoon
et al 1996). More sensitive nested-RT-PCR assays to detect both
prostate-specific antigen and prostate-specific membrane antigen
in histologically negative lymph nodes from prostate cancer
patients have found positive tumour marker expression in up to
79% of histologically negative cases. Nonetheless, as with other
current markers, the possibility of ectopic expression within
normal tissues in some patients remains to be ruled out (Ferrari
et al 1997).
While normal PBL samples taken from healthy individuals were
all usually negative, positive results were also obtained fromPIP expression in breast cancer 1007
British Journal of Cancer (1999) 81(6), 1002–1008 © 1999 Cancer Research Campaign
independent samples taken from the same individuals. It is already
known that PIP protein is present at relatively high levels in some
tissues other than breast, including skin, sweat glands and salivary
gland (Viacava et al, 1998; Wick et al, 1998). It therefore seems
possible that these false-positive results are attributable to contami-
nation from PIP expressing cells from sweat glands in the skin,
removed during venepuncture. If this interpretation is correct then
this problem might be minimized in any similar future study of PIP
by obtaining several blood samples at each venapuncture and
retaining only the final sample for analysis (de Graaf et al, 1997).
In this uniformly assessed tumour cohort increased PIP mRNA
expression was significantly associated with low-grade and ER
and PR positivity, both features that could be interpreted to indi-
cate either biological potential or cellular differentiation.
However, while PIP was not correlated with other indicators of
biological potential such as tumour size or nodal status, PIP
expression has previously been associated with cellular differenti-
ation. PIP mRNA in vitro in breast cells in culture is highest in
well-differentiated ER+ cells where PIP expression has also been
shown to be influenced by steroid hormones (Murphy et al, 1987)
and expression in non-neoplastic and neoplastic breast tissues in
vivo has been associated with specific morphological features of
apocrine cellular differentiation (Haagensen et al, 1990). It should
be noted that while our results are in agreement with the trends
seen in other recent studies (Hall et al, 1998; Bundred et al, 1990),
previous IHC studies, several larger than the present one
(Mazoujian et al, 1989; Wick et al, 1989), have not established an
association with these parameters. However, levels of PIP protein
in breast cancer tissue, unlike PIP mRNA, may be affected by the
fact that PIP is a secreted protein that is present at high levels in
breast duct secretions and the serum and so can originate from
adjacent breast tissues or other tissue normal tissues (Haagensen
et al, 1990; Manni et al, 1984).
We conclude that the PIP gene has potential as a marker of
breast micrometastasis. This is supported by the following
attributes: (1) PIP is expressed by most primary breast tumours,
(2) expression is often conserved in nodal metastases, and (3) this
gene is not expressed in several tissues that are often targets of
breast tumour metastasis. In common with several other genes
proposed as tumour markers, our results demonstrate the potential
for false-negative and false-positive results. The impact of this
on the clinical identification of true micrometastases should be
recognized and strategies developed to minimize these errors
through parallel assessment of unrelated tumour markers.
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